207 related articles for article (PubMed ID: 18379785)
1. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Messersmith WA; Jimeno A; Ettinger D; Laheru D; Brahmer J; Lansey D; Khan Y; Donehower RC; Elsayed Y; Zannikos P; Hidalgo M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):181-8. PubMed ID: 18379785
[TBL] [Abstract][Full Text] [Related]
2. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Gore L; Rivera E; Basche M; Moulder-Thompson SL; Li J; Eppers S; Grolnic S; O'Bryant C; Cleere D; Elsayed YA; Eckhardt SG
Invest New Drugs; 2012 Oct; 30(5):1942-9. PubMed ID: 21931969
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
von Mehren M; Bookman M; Meropol NJ; Weiner LM; Sherman E; Li J; Knoblauch R; Parekh T; Cohen RB
Cancer Chemother Pharmacol; 2015 May; 75(5):1047-55. PubMed ID: 25791363
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
Sessa C; Del Conte G; Christinat A; Cresta S; Perotti A; Gallerani E; Lardelli P; Kahatt C; Alfaro V; Iglesias JL; Fernández-Teruel C; Gianni L
Invest New Drugs; 2013 Oct; 31(5):1236-43. PubMed ID: 23467812
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
von Mehren M; Schilder RJ; Cheng JD; Temmer E; Cardoso TM; Renshaw FG; Bayever E; Zannikos P; Yuan Z; Cohen RB
Ann Oncol; 2008 Oct; 19(10):1802-9. PubMed ID: 18497430
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.
Vidal L; Magem M; Barlow C; Pardo B; Florez A; Montes A; Garcia M; Judson I; Lebedinsky C; Kaye SB; Salazar R
Invest New Drugs; 2012 Apr; 30(2):616-28. PubMed ID: 20927639
[TBL] [Abstract][Full Text] [Related]
9. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Chuk MK; Aikin A; Whitcomb T; Widemann BC; Zannikos P; Bayever E; Balis FM; Fox E
Pediatr Blood Cancer; 2012 Nov; 59(5):865-9. PubMed ID: 22847981
[TBL] [Abstract][Full Text] [Related]
11. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
Ueda T; Kakunaga S; Ando M; Yonemori K; Sugiura H; Yamada K; Kawai A
Invest New Drugs; 2014 Aug; 32(4):691-9. PubMed ID: 24696229
[TBL] [Abstract][Full Text] [Related]
13. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.
Pardo B; Salazar R; Ciruelos E; Cortés-Funes H; García M; Majem M; Montes A; Cuadra C; Soto-Matos A; Lebedinsky C; Alfaro V; Paz-Ares L
Med Oncol; 2012 Sep; 29(3):2240-50. PubMed ID: 21660618
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Sessa C; Cresta S; Noberasco C; Capri G; Gallerani E; De Braud F; Zucchetti M; D'Incalci M; Locatelli A; Marsoni S; Corradino I; Minoia C; Zintl P; Gianni L
Eur J Cancer; 2009 Aug; 45(12):2116-22. PubMed ID: 19419856
[TBL] [Abstract][Full Text] [Related]
16. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
[TBL] [Abstract][Full Text] [Related]
17. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A
Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.
Tassinari D; Drudi G; Panzini I; Pasini G; Arcangeli V; Fochessati F; Gianni L; Mianulli AM; Oliverio G; Pasquini E; Sartori S; Ravaioli A
Int J Clin Oncol; 2001 Dec; 6(6):279-83. PubMed ID: 11828946
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB
Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]